2022 IPO market kicks off with 3 biotechs set to trade on Friday

Renaissancecap...2022-01-04

The 2022 IPO market is wasting no time. Three biotechs launched their offerings on Monday, set to be the first IPOs of the new year. Trading is set for Friday. All three plan to raise more than $100 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Mimiso
2022-01-04
Mimiso
Biotech will be big!!
hj489
2022-01-04
hj489
Good news
PBL77
2022-01-04
PBL77
Like pls

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117922225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-04 14:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117922225","market":"us","top_or_hot":-1,"title":"2022 IPO market kicks off with 3 biotechs set to trade on Friday","media":"Renaissancecap...","content":"<div>\n<p>The 2022 IPO market is wasting no time. Three biotechs launched their offerings on Monday, set to be the first IPOs of the new year. Trading is set for Friday. All three plan to raise more than $100 ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89906/2022-IPO-market-kicks-off-with-3-biotechs-set-to-trade-on-Friday\">Source Link</a>\n\n</div>\n","source":"lsy1619493174116","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 IPO market kicks off with 3 biotechs set to trade on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 IPO market kicks off with 3 biotechs set to trade on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-04 14:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/89906/2022-IPO-market-kicks-off-with-3-biotechs-set-to-trade-on-Friday><strong>Renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The 2022 IPO market is wasting no time. Three biotechs launched their offerings on Monday, set to be the first IPOs of the new year. Trading is set for Friday. All three plan to raise more than $100 ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89906/2022-IPO-market-kicks-off-with-3-biotechs-set-to-trade-on-Friday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIGL","symbol_name":"Vigil Neuroscience, Inc.","start_time":0,"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89906/2022-IPO-market-kicks-off-with-3-biotechs-set-to-trade-on-Friday","article_id":"1117922225","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117922225","pubTimestamp":1641278425,"columns":[],"sourceInfo":{"source_id":"lsy1619493174116","name":"renaissancecapital"},"weMediaInfo":null,"summary":"The 2022 IPO market is wasting no time. Three biotechs launched their offerings on Monday, set to be","collect":0,"end_time":0,"defaultTopTitle":"renaissancecapital.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIGL":"Vigil Neuroscience, Inc.","CINC":"CinCor Pharma, Inc.","AMLX":"Amplify YieldShares Oil Hedged MLP Income ETF"},"translate_title":"2022年IPO市场启动，3家生物技术公司将于周五交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":0.9,"CINC":0.9,"VIGL":0.9},"content_text":"The 2022 IPO market is wasting no time. Three biotechs launched their offerings on Monday, set to be the first IPOs of the new year. Trading is set for Friday. All three plan to raise more than $100 million apiece, and one is targeting a market cap of more than $1 billion.Thanks to the recent trend of accelerated roadshows, the three deals will mark a record as the earliest IPO pricings (ex-SPAC) in a given year in at least 25 years.As we noted in our2021 US IPO Market Review, new issuers are starting the year on challenging footing due to recent underperformance. 94 biotechs went public in 2021; the group averaged a first-day return of 21%, but closed Monday with an average loss of -20% from the offer price.Amylyx PharmaceuticalsAmylyx is developing oral small molecule therapies for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and a broad range of neurodegenerative diseases. The company believes its lead candidate, AMX0035, is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. Based on its Phase 2 data, the company submitted an NDS in Canada and an NDA to the FDA in 2021, and plans to submit an MAA in Europe in the 1Q22. While it believes it may gain approval with Phase 2 data, Amylyx also recently initiated a 48-week Phase 3 trial of AMX0035 for the treatment of ALS in the US and Europe.Primary backers: Morningside Group, SUNU Ventures, Viking Global Investors.CinCor PharmaCinCor Pharma's lead candidate, CIN-107, has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In 2021, CinCor Pharma initiated several different trials for patients suffering from hypertension as well as primary aldosteronism, or PA. The company is also exploring its utility in ameliorating complications of chronic kidney disease, or CKD, with plans to initiate trials in the first half of 2022.Primary backers: Sofinnova Investments, Sofinnova Partners, 5AM Ventures, CinRx Pharma, General Atlantic.Vigil NeuroscienceVigil is utilizing a precision medicine approach to develop a pipeline of therapies, initially addressing genetically defined patient subpopulations, that it believes will activate and restore immune cell function within the brain. Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In November 2021, the FDA cleared Vigil's IND for VGL101 in ALSP. The company initiated its first-in-human Phase 1 trial in December, and topline data is expected in the 2H22.Primary backers: Atlas Venture, Northpond Ventures, Vida Ventures, Amgen.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9001554650,"gmtCreate":1641285363484,"gmtModify":1676533593021,"author":{"id":"3571221470230297","authorId":"3571221470230297","name":"Mimiso","avatar":"https://static.tigerbbs.com/2e373fdea92862942121c3164e7dc9e5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3571221470230297","authorIdStr":"3571221470230297"},"htmlText":"Biotech will be big!!","listText":"Biotech will be big!!","text":"Biotech will be big!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001554650","repostId":1117922225,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9001555555,"gmtCreate":1641285301503,"gmtModify":1676533592997,"author":{"id":"4102918773726210","authorId":"4102918773726210","name":"hj489","avatar":"https://static.tigerbbs.com/f76bb306d5a5646fd7fa385e0fa593c8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4102918773726210","authorIdStr":"4102918773726210"},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001555555","repostId":1117922225,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9001567808,"gmtCreate":1641278674266,"gmtModify":1676533592480,"author":{"id":"4087190594214920","authorId":"4087190594214920","name":"PBL77","avatar":"https://static.tigerbbs.com/8ef4f93ba3e261ac276aef28c4467365","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4087190594214920","authorIdStr":"4087190594214920"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001567808","repostId":1117922225,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":31,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117922225"}